Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
YIELD10 BIOSCIENCE, INC. (YTEN)
|
Add to portfolio |
|
|
|
| Price: |
$10.54
| | Metrics |
| OS: |
6.11
|
M
| |
-2428
|
% ROE
|
| Market cap: |
$64.4
|
M
| |
-1211
|
% ROIC
|
|
Net cash:
|
$1.36
|
M
| |
$0.22
|
per share
|
|
EV:
|
$63.1
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($13.9)
|
M
| |
|
|
|
EBIT
|
($14.2)
|
M
| |
|
|
| EPS |
($2.78)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.5 | 0.6 | 0.8 | 0.8 | 0.6 | 0.9 | 1.2 | 1.4 |
| Revenue growth | -26.7% | -23.2% | -0.9% | 45.0% | -41.1% | -18.6% | -14.1% | -51.8% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.7 | 6.6 |
| Gross profit | 0.5 | 0.6 | 0.8 | 0.8 | 0.6 | 0.9 | -4.5 | -5.3 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -389.2% | -389.0% |
| Selling, general and administrative | 6.2 | 6.1 | 5.0 | 4.6 | 5.1 | 5.6 | 5.7 | 7.2 |
| Research and development | 7.8 | 6.2 | 5.4 | 4.8 | 4.8 | 4.6 | | |
| EBIT | -13.5 | -11.7 | -8.7 | -8.6 | -9.3 | -9.3 | -10.2 | -12.5 |
| EBIT margin | -2989.1% | -1904.2% | -1082.9% | -1066.5% | -1676.1% | -983.4% | -884.2% | -923.6% |
| Pre-tax income | -13.4 | -11.0 | -10.2 | -13.2 | -9.2 | -9.4 | -10.3 | -12.4 |
| Income taxes | 0.2 | 0.0 | 0.1 | -0.3 | 0.0 | 0.0 | -1.1 | 11.2 |
| Tax rate | | | | 1.9% | 0.0% | 0.0% | 10.7% | |
| Net income | -13.6 | -11.0 | -10.2 | -13.0 | -9.2 | -10.8 | -7.6 | -23.7 |
| Net margin | -3014.7% | -1796.6% | -1277.3% | -1607.4% | -1652.0% | -1146.5% | -656.1% | -1754.1% |
| |
| Diluted EPS | ($2.76) | ($2.33) | ($4.30) | ($35.50) | ($36.99) | ($3.29) | ($2.73) | ($0.50) |
| Shares outstanding (diluted) | 4.9 | 4.7 | 2.4 | 0.4 | 0.2 | 3.3 | 2.8 | 25.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|